Multicell

MultiCell Technologies is a biopharmaceutical company specializing in the development of therapeutics for liver diseases, cancer, and neurological disorders. The company is best known for its proprietary Fa2N-4 immortalized human hepatocyte cell line, which serves as a platform for drug discovery and toxicity testing. Its clinical pipeline has featured candidates like MCT-125 for Multiple Sclerosis-related fatigue and MCT-465 for hepatocellular carcinoma. MultiCell also operates through its subsidiary, MultiCell Immunotherapeutics, to develop antibody-drug conjugates and other targeted therapies. The company's technology has historically been licensed to major pharmaceutical firms for use in drug metabolism and safety studies.